news

1 October 2015 – Grace and Formac announce SilSol 6035 silica for drug delivery

4 May 2015 – Formac to receive EU financial support through Its Horizon 2020 scheme for the upscaling of its technology

15 December 2014 – FORMAC applies for Horizon 2020 project

1 October 2014 – Randy Mellaerts appointed R&D Director

26 June 2014 – Formac involved in major partnering events

6 February 2014 – Leading industry and academic experts to discuss drug delivery technologies to overcome bioavailability issues at Basel symposium

4 September 2013 – Formac to present at the Catalent Applied Drug Delivery Instituteā€™s 1st educational venue scheduled on October 4th ,2013

27 June 2013 – Michiel Van Speybroeck appointed Chief Scientific Officer

17 June 2013 – Formac receives final advice letter from the European Medicines Agency

4 June 2013 – Formac to present at the Catalent Applied Drug Delivery Institute "Overcoming Bioavailability Challenges" event on 12 June 2013

29 May 2013 – FORMAC will be attending Knowledge for Growth, organised by FlandersBio on the 30th of May in Ghent.

20 February 2013 – Formac Signs Feasibility Agreement with major German Pharma Company

14 February 2013 – Formac initiates procedure to obtain Scientific Advice from the European Medicines Agency

17 September 2012 – Meet with us in Boston or Chicago this October!

21 August 2012 – Formac invited to speak at the Drug Delivery Technologies & Formulation Conference, September 05-06, 2012 in Zurich, CH

23 May 2012 – Formac Pharmaceuticals signs feasibility agreement with major generic drug company

3 April 2012 – Formac to present during the Global Formulation and Drug Delivery Summit to be held in Amsterdam on April 16th-18th

20 March 2012 – Formac Pharmaceuticals reports positive outcome of phase 1 clinical study

6 January 2012 – Silica based drug delivery research published in Journal of Pharmaceutical Sciences

3 January 2012 – FORMAC announces the appointment of new R&D Director

18 October 2011 – FORMAC Pharmaceuticals initiates a phase 1 Proof-of-Concept (PoC) clinical trial for its silica-based drug delivery platform.

9 October 2011 – FORMAC will present its latest research results at the 2011 American Association of Pharmaceutical Scientists Meeting in Washington DC in the week of 24-28th of October 2011.

14 June 2011 – FORMAC Pharmaceuticals announces successful completion of Pre-Clinical Study demonstrating the safety of its proprietary ordered mesoporous silica (MeposilĀ®)

13 May 2011 – Successful collaboration between FORMAC PHARMACEUTICALS NV and FLAMAC,a division of SIM

10 March 2011 – FORMAC obtains EMA Orphan Drug Designation for its FP110 program

1 March 2011 – New website online